Medical policy
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's…
United Healthcare medical policy CS2024D0108F · Sep 23, 2025
Key facts
| Policy title | Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease - Community Plan Medical Benefit Drug Policy |
|---|---|
| Insurer | United Healthcare |
| Policy number | CS2024D0108F |
| Policy date | Sep 23, 2025 |
| Current policy | Yes |
| Insurer page | uhcprovider.com |
At a glance
- None 510(k)s referenced
- None PMAs referenced
- None De Novos referenced
- 1–9 Clinical trials referenced
- 10–99 Articles referenced
- None UDI devices referenced
- None NDC products referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Insurer medical policies
Insurer clinical and medical policies state when a payer covers a device, drug or procedure. Orca1 links each policy to the FDA submissions, trials and articles it cites. Policy text is not reproduced here.
Source: Health insurer clinical and medical policies (insurer as listed); cross-links by Orca1